Edwards Lifesciences Corporation (EW)

Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.

Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript

Arrowstreet Capital Limited Partnership reduced its position in Edwards Lifesciences Corporation (NYSE: EW) by 42.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 153,874 shares of the medical research company's stock after selling 112,182 shares during

Edgestream Partners L.P. lowered its stake in Edwards Lifesciences Corporation (NYSE: EW) by 97.0% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,695 shares of the medical research company's stock after selling 117,875 shares during the period. Edgestream Partners L.P.'s holdings in

Avalon Global Asset Management LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE: EW) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 55,000 shares of the medical research company's stock, valued at approximately $4,302,000. A

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportuniti.

Fisher Asset Management LLC lessened its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 96.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 316,392 shares of the medical research company's stock after selling 9,784,074 shares during the period. Fisher Asset Management LLC owned

American Century Companies Inc. decreased its position in shares of Edwards Lifesciences Corporation (NYSE: EW) by 82.4% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 224,366 shares of the medical research company's stock after selling 1,049,818 shares during the period. American

BLI Banque de Luxembourg Investments bought a new stake in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 61,500 shares of the medical research company's stock, valued at approximately $4,809,000. Several other large

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders.

Berry Wealth Group LP bought a new position in shares of Edwards Lifesciences Corporation (NYSE: EW) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,589 shares of the medical research company's stock, valued at approximately $202,000. A number of

AlphaCore Capital LLC purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,079 shares of the medical research company's stock, valued at approximately $163,000. A number of

Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.

Nuwellis (NASDAQ: NUWE - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership. Valuation and Earnings This table compares Nuwellis and Edwards

The portfolio generated a modestly positive absolute return in Q3, but it trailed the MSCI All Country World Small Mid Index. The Q3 underperformance was driven by stock selection in the IT, financials and consumer discretionary sectors. On the positive side, stock selection in the health care and industrials sectors was the strongest contributor to performance.

NEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association's Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28 million people living with heart valve disease worldwide. In the U.S. alone, valve disease contributes to more than 60,000 deaths annually, many driven by delayed diagnosis or treatment. Through this initiative, the American Heart Association is establishing valve dis.